Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Prostate: early-phase trial registry

2 of 6 indexed Prostate trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,866 of 28,707 conditions by registered trial count.

6 US clinical trials · 2 currently recruiting · #2,866 of 28,707 conditions by registered trial count

Prostate: 6 US clinical trials tracked, 2 recruiting.

Prostate is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Conjupro Biotherapeutics, running 1 of these trials.

Enrollment posture brief

Registry condition prostate

OPEN 2 | RECR 33% | LATE 0 | EARLY 4 | RANK #2866 | SPON 1

Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)

Acute Hypoxemic Respiratory 66.7%Abdominal Aortic Aneurysms50%Acupuncture50%Acute Lymphoblastic Leukemia50%Prostate (this)33%
Open-enrollment share among volume-matched conditions near Prostate

Prostate lists 2 open slots (33% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Prostate on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Prostate is recruiting below its size-band peers.

    2 of 6 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Prostate research.

    Conjupro Biotherapeutics accounts for 1 of 6 trials (16.7%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Typical Prostate enrolment sits around 275 participants.

    Median target enrolment is 275 among the 6 trials that report a genuine target (sentinel values excluded). 3 of those (50%) plan for fewer than 100 participants.

  4. Prostate research is mostly interventional.

    5 interventional and 1 observational studies make up this index (83.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 23

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 3

Named interventions

Most-linked intervention names on Prostate records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

tadalafil Drug
1 trials
Flotufolastat F 18 Drug
1 trials
TheraSphere PCa Device
1 trials
SYS6043 Drug
1 trials
Olaparib Drug
1 trials
placebo Drug
1 trials

US sites by state

Facility locations filed on Prostate trials. A trial with sites in several states counts in each.

Maryland 2 trials
Illinois 2 trials
Florida 2 trials
Virginia 1 trials
Texas 1 trials
Pennsylvania 1 trials
Nebraska 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Prostate page

6 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Prostate condition card totals 6 registered trials; most-linked intervention tadalafil; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.